A Phase 1/2 Study of CPI-0209 Monotherapy and in Combination with Other Therapy in Patients with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Have a life expectancy of = 12 weeks. 2) Have measurable disease or non-measurable disease per RECIST 1.1. 3) Provide a baseline archival tumor sample (Phase 1) or fresh tumor biopsy at Baseline (Phase 2).

You may not be eligible for this study if the following are true:

  • 1) Previous solid organ or hematopoietic cell transplant. 2) Known symptomatic untreated brain metastases. 3) Prior anticancer treatment • Prior systemic anticancer treatment with chemotherapy, targeted therapy, small molecule, antibody, or investigational anticancer therapy (includes prior PD-1 or PD-L1 therapy), or other anticancer therapeutic within 4 weeks (or 5 half-lives), whichever is shorter, before the first dose of study drug (6 weeks washout for nitrosoureas or mitomycin C). 4) Previous treatment with an EZH2 inhibitor (all patients).


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.